An Evaluation of the CHADS(2) Stroke Risk Score in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Revascularization

JM Ruiz-Nodar, F Marin, S Manzano-Fernandez, J Valencia-Martin, JA Hurtado, V Roldan, J Pineda, E Pinar, F Sogorb, M Valdes, Gregory Lip

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: There are various schemas designed to stratify the risk of thromboembofism (TE) in patients with atrial fibrillation (AF), of which the CHADS(2) (congestive heart failure, hypertension, age >= 75 y, diabetes, stroke [doubled]) score is the most widely studied. We evaluated whether the CHADS(2) score was adequate for TE risk stratification while assessing cardiac risk in patients with AF revascularized with coronary artery stents. Methods: We reviewed 604 consecutive patients with AF treated with at least one stent between 2001 and 2008 in relation to TE risk using CHADS(2) score. We stratified our patients with a CHADS(2) score 1 as high risk (and, hence, requiring anticoagulation; group 2: n = 411, 68%). We determined the benefits and/or risks of oral anticoagulation (OAC) therapy in both cohorts. Results: Completed follow-up was achieved in 90.4% (mean 642.2 days). Group 1 event-free survival was better than group 2 (major adverse cardiovascular events [MACEs], log-rank test P =.03; and death, log-rank test P =.03). In group 1, event-free survival was better on OAC vs non-OAC use (death 5% vs 15%, P =.04; MACE 10% vs 26%, P
Original languageEnglish
Pages (from-to)1402-1409
Number of pages8
JournalChest
Volume139
Issue number6
DOIs
Publication statusPublished - 1 Jun 2011

Fingerprint

Dive into the research topics of 'An Evaluation of the CHADS(2) Stroke Risk Score in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Revascularization'. Together they form a unique fingerprint.

Cite this